What should I do if I become resistant to Pertuzumab?

The dual-targeted combination of Pertuzumab and trastuzumab and cytotoxic chemotherapy are the main treatment options for patients with early-stage HER2-positive breast cancer. Antibody drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) can also improve the prognosis of patients with metastatic breast cancer. However, resistance to targeted therapies eventually develops.

If resistance to pertuzumab occurs, doctors may confirm it by checking tumor markers, imaging examinations, and genetic testing. If resistance has been confirmed, they can consider switching to other drugs for HER2-positive breast cancer, such as trastuzumab or tocilizumab (T-DM1). These drugs may produce a better response to drug resistance. While switching to other drugs, you can consider using a combination of multiple anti-cancer drugs. The trial successfully established in vivo tumor models resistant to trastuzumab and pertuzumab or T-DM1 and found that TAS0728 monotherapy was effective against tumors resistant to these therapies.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.